Eton Pharmaceuticals Q1 2024 GAAP EPS $(0.03) Beats $(0.07) Estimate, Sales $7.966M Miss $8.000M Estimate
Eton Pharmaceuticals Q1 2024 GAAP EPS $(0.03) Beats $(0.07) Estimate, Sales $7.966M Miss $8.000M Estimate
伊頓製藥2024年第一季度GAAP每股收益美元（0.03）超過預期（0.07），銷售額爲796.6萬美元，低於8000萬美元的預期
Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.07) by 57.14 percent. This is a 70 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $7.966 million which missed the analyst consensus estimate of $8.000 million by 0.43 percent. This is a 50.19 percent increase over sales of $5.304 million the same period last year.
伊頓製藥（納斯達克股票代碼：ETON）公佈的季度虧損爲每股0.03美元，比分析師普遍預期的0.07美元（0.07美元）高出57.14％。這比去年同期每股虧損0.10美元（0.10）增長了70％。該公司公佈的季度銷售額爲796.6萬美元，比分析師共識估計的800萬美元低0.43％。這比去年同期的530.4萬美元的銷售額增長了50.19％。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。